Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

TransEnterix CEO, Todd Pope, featured in TIME's "The 50 Most Influential People in Health Care of 2018"

October 18, 2018
Todd Pope, TransEnterix President and CEO, was recently named to TIME's "The 50 Most Influential People in Health Care of 2018." The list honors fifty people transforming health care, across…
READ MORE

TapImmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing

October 18, 2018
Jacksonville, FL, October 17, 2018 —TapImmune Inc. (NASDAQ: TPIV), today announced the closing of the previously announced merger with privately-held Marker Therapeutics, Inc. In connection with the merger, TapImmune Inc.…
READ MORE

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

October 17, 2018
AUSTIN, Texas, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic…
READ MORE